课题基金 / 基金详情

Role and regulation of GnRH and receptors in Cisplatin resistant ovarian cancer

Role and regulation of GnRH and receptors in Cisplatin resistant ovarian cancer
GnRH 及其受体在顺铂耐药卵巢癌中的作用和调节
批准号:
7937435
负责人:
Rajagopala Sridaran
金额:
$0.79万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
未结题
起止时间:
2010-05-13 至

项目摘要

项目成果

Rajagopala Sridaran的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ovarian cancer (OVCA) is the most lethal of the gynecological malignancies and chemoresistance presents a major hurdle for successful treatment. The mechanism involved in the regulation of chemo- sensitivity is not completely known. The presence of gonadotropin releasing hormones (GnRHs) and their receptors (GnRHRs) in human ovarian surface epithelium raises the possible existence of an autocrine regulatory loop in OVCA and that this system is involved in cisplatin (CDDP)-induced apoptosis. We hypothesize that GnRHs and GnRHRs are important in the control of chemosensitivity and that their dysregulation may confer chemoresistance in OVCA. The objective of our study is to examine the expression and the role of GnRH and its receptor in the regulation of CDDP sensitivity in OVCA, using pairs of chemo-sensitive and chemoresistant human OVCA cell lines with same genetic background and established p53 and Akt status. sIRNA, dominant negatives (DN) and sense cDNA will be used. In Aim 1, regulation of GnRH and GnRHR expression in chemosensitlve (OV2008 and A2780) and chemoresistant (CI 3* and A2780cp) cells treated with CDDP will be determined by RIA, immunocytochemistry, Western blotting and qRT-PCR. Use of p53 mutant cell line will delineate if p53 is involved in CDDP-induced GnRH-mediated apoptosis. In Aim 2, the functionality of endogenous GnRHs and GnRHRs will be assessed by determining if (a) knockdown of GnRH and their receptors in chemosensitlve OVCA cells confer resistance in these cells to CDDP (decreased apoptosis); (b) forced expression of GnRH receptors and/or addition of exogenous GnRH would sensitize chemoresistant OVCA cells to CDDP (increased apoptosis). In Aim 3, we will determine the mechanism of dysregulation of the GnRH system in chemoresistance, by investigating Ca++ signaling and apoptotic response of both sensitive and resistant OVCA cells to CDDP with/without GnRH treatment. We will determine the role of p53 and Akt in this regulation in OVCA cell lines with wild type and mutant p53, p53 gene silencing and reconstitution, expression of constitutively activated as well as DN-Akt. This study will improve the understanding of the molecular mechanism of chemoresistance in ovarian cancer and offer new insight in the development of novel therapeutic strategies for chemoresistant ovarian cancer. PUBLICH HEALTH RELEVANCE: Chemoresistance is a major hurdle for successful ovarian cancer treatment. This study will improve the understanding of chemoresistance in ovarian cancer and offer new insight in the development of novel therapeutic strategies for ovarian cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role and regulation of GnRH and receptors in Cisplatin resistant ovarian cancer
Genomic Fingerprint of PGF2alpha and LH actions on the *
  • 批准号:
    7125944
  • 项目类别:
  • 资助金额:
    $6.93万
  • 财政年份:
    2005
  • 负责人:
    Rajagopala Sridaran
  • 依托单位:
Genomic Fingerprint of PGF2alpha/LH actions on luteal
  • 批准号:
    7046342
  • 项目类别:
  • 资助金额:
    $7.1万
  • 财政年份:
    2005
  • 负责人:
    Rajagopala Sridaran
  • 依托单位:
INDUCTION OF APOPTOSIS BY GONADOTROPIN RELEASING HORMONE DURING PREGNANCY
  • 批准号:
    6496311
  • 项目类别:
  • 资助金额:
    $15.94万
  • 财政年份:
    2001
  • 负责人:
    Rajagopala Sridaran
  • 依托单位:
国内基金
海外基金
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
  • 批准号:
    82371634
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵福军
  • 依托单位:
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
  • 批准号:
    82371651
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵栋
  • 依托单位:
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
  • 批准号:
    82370798
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王晓
  • 依托单位:
精氨酸调控骨髓Tregs稳态在脓毒症骨髓功能障碍中的作用研究
  • 批准号:
    82371770
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    宁铂涛
  • 依托单位: